NCT02812238View on ClinicalTrials.gov

Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

NACompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 23, 2016

Primary Completion Date

August 28, 2018

Study Completion Date

August 28, 2018

Conditions
AtherosclerosisDiabetesCoronary Artery Disease
Interventions
DIETARY_SUPPLEMENT

Nicotinamide riboside (NR)

NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.

DRUG

Placebo

Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT02812238 - Study to Evaluate the Effect of Nicotinamide Riboside on Immunity | Biotech Hunter | Biotech Hunter